Abstracts tagged "renal disease and rheumatoid arthritis (RA)"

Abstract Number: 1144 • 2018 ACR/ARHP Annual Meeting
Risk of Osteoporotic Fractures in Patients with Rheumatoid Arthritis and End Stage Renal Disease. Findings from the Usrds Database
Renee Peterkin-McCalman, Jennifer Waller, Brian Le, Alyce Oliver, Evan Manning, Stanley Nahman and Laura Carbone, Medical College of Georgia at Augusta University, Augusta, GA
Background/Purpose: Rheumatoid arthritis (RA) and End Stage Renal Disease (ESRD) are independent risk factors for osteoporotic fractures. Approximately one percent of persons with ESRD have…
Abstract Number: 537 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Incident Chronic Kidney Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies
Patompong Ungprasert¹ and Sukit Raksasuk², ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Increased Risk of Incident Chronic Kidney Disease among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis of Cohort Studies AbstractBackground/Purpose: Patients with rheumatoid arthritis (RA)…
Abstract Number: 882 • 2018 ACR/ARHP Annual Meeting
Predictors of Chronic Kidney Disease in US Veterans with Rheumatoid Arthritis
J. Steuart Richards¹, Richard Amdur², Grant W. Cannon³ and Gail S. Kerr⁴, ¹Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, ²Lead Biostatistician, Medical Faculty Associates Clinical Professor, Dept. of Surgery, George Washington University School of Medicine & Health Sciences, Washington, DC, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC
Background/Purpose: Chronic kidney disease (CKD) is a comorbidity that may affect patients with rheumatoid arthritis (RA). CKD restricts the use of disease modifying anti-rheumatic drugs…
Abstract Number: 1570 • 2015 ACR/ARHP Annual Meeting
End Stage Renal Disease (ESRD) in Patients with Rheumatoid Arthritis
Sunita Paudyal¹, Monique Bethel², Frances Yang¹, Alyce Oliver¹, Michael Skelton¹, Christopher Rice¹, Brian Le³, Shilpa Brown¹, Stanley Nahman¹ and Laura Carbone⁴, ¹Georgia Regents University, Augusta, GA, ²Internal Medicine, Georgia Regents University, Augusta, GA, ³Medicine, Georgia Regents University, Augusta, GA, ⁴Rheumatology, Georgia Regents University, Augusta, GA
Background/Purpose: Substantial progress has been made in the treatment of rheumatoid arthritis (RA) and life expectancy has increased. As the population of patients with RA…
Abstract Number: 1413 • 2014 ACR/ARHP Annual Meeting
The Prevalence of Renal Impairment in Patients with Rheumatoid Arthritis
Marion Couderc Sr.¹, Martin Soubrier², Bruno Pereira³, Aurelien Tiple⁴, Melanie Gilson⁵, Bruno Fautrel⁶, Sophie Pouplin⁷, Emmanuelle Dernis Labous⁸, Laure Gossec⁹, Cécile Gaujoux-Viala¹⁰ and Maxime Dougados¹¹, ¹Chu G.Montpied, Clermont Ferrand, France, ²Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Nephrology, CHU, Clermont-Ferrand, France, ⁵Rheumatology, CHu Grenoble, Grenoble, France, ⁶Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁷Rheumatology, Rouen University Hospital, Rouen, France, ⁸Rhumatologie, Ch Du Mans, Le Mans, France, ⁹Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ¹⁰EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ¹¹Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: To assess the prevalence and associations of renal dysfunction in patients with rheumatoid arthritis (RA). Methods: COMEDRA is a French nationwide cross-sectional multicentre study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].